Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.

Pyrazinamide (PZA) is a first-line drug for short-course tuberculosis therapy. Resistance to PZA is usually accompanied by loss of pyrazinamidase (PZase) activity in Mycobacterium tuberculosis. PZase converts PZA to bactericidal pyrazinoic acid, and the loss of PZase activity is associated with PZA...

Descripción completa

Detalles Bibliográficos

Publicado en:	Antimicrob Agents Chemother
Autores principales:	Scorpio, A, Lindholm-Levy, P, Heifets, L, Gilman, R, Siddiqi, S, Cynamon, M, Zhang, Y
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	American Society for Microbiology (ASM) 1997
Materias:	Research Article
Acceso en línea:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC163747/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9055989/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.41.3.540
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!